- Sanofi to invest $40 million at an as-converted price of $7.44 per share of common stock- - Sanofi to receive an exclusive right of first negotiation for license of Company's small molecule TREM2 agonist program, including VG-3927, currently in phase 1 clinical studies - - Company expects proceeds to extend cash runway into 2026 - WATERTOWN, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia ...

Availability of the Q2 2024 Aide-mémoire Paris, France – June 25, 2024. Sanofi announced that its Q2 2024 Aide-mémoire is available on the "Investors" page of the company's website: https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/q2-results-2024 As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items and exclusivity losses as well as the forei ...

ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran Seven oral presentations across the hemophilia portfolio reinforce Sanofi's commitment to bring potential first- and best-in-class treatments to the rare blood disorders community Interim results from the long-term XTEND-ed phase 3 study demonstrate once-weekly ALTUVIIIO continues to provide highly effective bleed protection New ATLAS phase 3 study data reinforce the potential of fitusiran to provide prophylaxis for peo ...

STOCKHOLM, June 19, 2024 /PRNewswire/ -- Sobi® today announced the European Commission has granted Marketing Authorisation for ALTUVOCT™ (efanesoctocog alfa), for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A. ALTUVOCT is a high-sustained factor VIII replacement therapy for all ages and any disease severity. Children, adolescents, and adults can experience non-haemophilia factor VIII activity levels (above 40%) for a significant part of the week with once-weekly proph ...

Collaboration will leverage Belharra’s proprietary, non-covalent chemoproteomics platform to identify and advance small molecules against Sanofi-designated immunology targets Sanofi to lead further preclinical, clinical and commercial activities of candidates Belharra is eligible to receive up to $40 million in upfront and near-term milestone payments, and up to nearly $700 million in aggregate research, development and commercial milestone payments and royalties on net sales SAN MATEO, Calif. AND SAN DIEGO ...

Panama7 Shares of Sanofi (NASDAQ:SNY) have yet to fully recover from the business strategy change the company dropped on investors in October 2023. At the time, Sanofi announced plans to increase R&D investments to “drive long-term growth and enhance shareholder value” and to separate its consumer healthcare business to enable greater focus and resources to the biopharma business. This was a shocking turn of events for a slow-growing, dividend-paying company, and I understand the reluctance of the sharehold ...

DMP Sanofi (NASDAQ:SNY) (OTCPK:SNYNF) is one of the largest pharmaceutical companies in Europe, with a leading position in the global anti-inflammatory therapeutics market. Investment thesis Wall Street's indifference to France's largest pharmaceutical company is reflected in its share price continuing to move sideways despite its rich pipeline of approved and experimental medicines, rising dividend payouts, and relatively low debt. In my estimation, in addition to the product candidates, some of which coul ...

Sanofi completes acquisition of Inhibrx, Inc. Paris, May 30, 2024. Sanofi announced today the completion of its acquisition of Inhibrx, Inc. (“Inhibrx”). The acquisition adds SAR447537 (formerly INBRX-101) to Sanofi’s rare disease pipeline, underscoring the company’s commitment to pursuing differentiated and potential best-in-class medicines that build upon our existing strengths and capabilities. SAR447537 is a human recombinant protein that holds the promise of allowing alpha-1 antitrypsin deficiency (AAT ...

BARCELONA, Spain, May 28, 2024 /PRNewswire/ -- Sanofi is all in on AI and wants to become the first biopharma company powered by AI at scale. The company is using AI to chase the miracles of science by accelerating drug discovery, enhancing clinical trial design and improving the manufacturing and supply of medicines and vaccines to get them to patients in need faster. Bluecrux's digital supply chain twin technology, Axon, plays a critical role in Sanofi's digital supply chain transformation. Delivering mir ...

Sanofi (SNY) announced that the FDA has accepted the supplemental biologics license application (sBLA), seeking expanded use of its multiple myeloma drug, Sarclisa (isatuximab). The sBLA seeks approval for Sarclisa in combination with Velcade (bortezomib), Bristol-Myers’ (BMY) Revlimid (lenalidomide) and dexamethasone (VRd) for the treatment of patients with newly diagnosed multiple myeloma (NDMM) who are transplant-ineligible. With the FDA granting a priority review to the sBLA, a decision from the regulat ...